Social Media Ideas for Silence Therapeutics

Merck KGaA to acquire Silence Therapeutics for $1.3 billion

Merck KGaA to buy Silence Therapeutics in all-cash deal

<![CDATA[Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion ]]>

Merck KGaA bets on RNAi with $1.3B Silence buyout

The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.

Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer

The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera. Silence’s RNA therapy offers a different approach and...

Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut

ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare...

Next-gen RNAi drugmaker City prices $200M IPO

The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi treatments that get into tissues outside the liver. 

Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on...

RNAi drug specialist ADARx raises $446M IPO

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

City Therapeutics’ Upsized IPO Raises $200M to Bring RNAi Drugs Beyond the Liver

City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The company’s technology for designing RNAi drugs and delivering...

Inhaled Suppressor tRNA Restores Gene Function in Cystic Fibrosis Models

A preclinical study showed how chemically enhanced suppressor tRNAs combined with a lung-targeted delivery system can restore production of a critical protein in models of cystic f...

<![CDATA[Pharmaceutical Executive Daily: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Th...

Silence Laboratories is building privacy-first cybersecurity technology

Palo Alto-based startup Silence Laboratories works with around 35 clients globally, including a top US bank, and has research published in more than 10 Tier-1 publications.

Pelacarsen

Pelacarsen Anonymous (not verified) Sun, 09/13/2026 - 18:52 field_thread_url https://cafepharma.com/boards/threads/pelacarsen.718555/ bo...

Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease

New financing will help Moonwalk Biosciences expand its pipeline of siRNA medicines targeting adipose tissue while building out its proprietary drug discovery platform. The post Mo...

<![CDATA[Roundup: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy, Enodia Therapeut...

Novartis RNA drug falls short in rare muscle disease study

The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.

<![CDATA[METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies]]&gt...

<![CDATA[Roundup: Sling Therapeutics Closes $123 Million Series C Financing, Circle Pharma Announces $92.5 Million Se...

<![CDATA[Caribou Biosciences Discontinues Development for Vispa-cel & CB-011 CAR-T Cell Therapy Programs ]]>

Gossamer Bio submits NDA for seralutinib for pulmonary arterial hypertension

ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.

This week in charts: a big year for RNAi developers

The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi developers, and the funding that came with it.